Skip to main
HRMY

HRMY Stock Forecast & Price Target

HRMY Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Harmony Biosciences Holdings Inc. is experiencing significant growth potential, with WAKIX sales projected to rise from approximately $160 million in 2020 to over $700 million by 2024 due to its safety and convenience advantages for treating narcolepsy. The company's advancement in its pipeline, including the potential of pitolisant-GR to improve patient adherence by eliminating dose titration needs, further enhances the commercial viability of its products, with anticipated regulatory filings for new drug applications in the coming years. Additionally, Harmony's strong balance sheet supports ongoing research and development initiatives, positioning it favorably as a compelling growth story in the neurology sector.

Bears say

Harmony Biosciences Holdings Inc. faces a negative outlook primarily due to the disappointing results of its pivotal Phase 3 trial for ZYN002, which failed to meet primary endpoints because of an unexpectedly high placebo response. Additionally, competitive pressures in the sodium oxybate market and the potential for slowed growth in new patient additions for WAKIX contribute to concerns about future revenue generation. The uncertainty surrounding the success of ongoing clinical trials for other drug candidates further exacerbates the company's financial risks, indicating challenges in maintaining a robust therapeutic pipeline.

HRMY has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harmony Biosciences Holdings (HRMY) Forecast

Analysts have given HRMY a Strong Buy based on their latest research and market trends.

According to 7 analysts, HRMY has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harmony Biosciences Holdings (HRMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.